Malignant Mesothelioma Market Size and Growth Forecast for Businesses 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Malignant Mesothelioma Market Size During 2025–2029?

The malignant mesothelioma market has experienced substantial expansion in recent years. It is projected to expand from $2.46 billion in 2024 to $2.61 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 5.9%. This past growth can be ascribed to several factors, including heightened investments in oncology research, an increase in asbestos-related litigation cases, greater hospital investments, an expanding aging population, and the development of AI-driven drug discovery platforms.

The market for malignant mesothelioma is anticipated to experience substantial expansion in the coming years, projected to reach $3.32 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.3%. This projected growth during the forecast period stems from factors such as the increasing acceptance of immunotherapy treatments, a heightened emphasis on personalized medicine, the expanding use of minimally invasive surgical procedures, rising healthcare spending, and an increasing volume of clinical trials. Key trends expected over this period encompass progress in immunotherapy, tailored medical approaches, efforts for early detection, innovative minimally invasive surgical methods, and new regulatory approvals.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22046&type=smp

What Are The Main Drivers Boosting The Malignant Mesothelioma Industry’s Expansion?

Enhanced clinical research and development initiatives are anticipated to boost the malignant mesothelioma market’s future expansion. These R&D endeavors encompass conducting scientific studies and trials aimed at creating novel pharmaceuticals, therapeutic methods, and medical apparatus. Such efforts involve rigorously testing the safety, effectiveness, and potential adverse reactions of new products through controlled clinical trials. The increase in clinical research and development activities stems from a rising demand for new and improved treatments, especially considering the growing prevalence of chronic diseases and complex medical conditions. Research and development efforts propel advancements in malignant mesothelioma by expediting progress in diagnostics, therapies, and targeted treatments, thereby fostering innovative approaches to enhance early detection, improve patient survival rates, and devise more effective, less invasive treatment alternatives. For instance, in January 2025, as per the Anadolu Agency, a state-run news agency from Turkey, clinical trials represent nearly 40% of the U.S. pharmaceutical research budget, totaling approximately $7 billion annually. Thus, the escalating research and development activities are driving the growth of the malignant mesothelioma market.

What Are The Emerging Segments Gaining Attention In The Malignant Mesothelioma Market?

The malignant mesotheliomamarket covered in this report is segmented –

1) By Treatment Type: Chemotherapy; Radiation Therapy; Surgery; Immunotherapy; Targeted Therapy

2) By Route Of Administration: Oral; Intravenous; Injectable; Topical

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies

4) By End-User: Hospitals; Oncology Clinics; Rehabilitation Centres; Research Laboratories

Subsegments:

1) By Chemotherapy: Alkylating Agents; Antimetabolites; Combination Therapy

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Intensity-Modulated Radiation Therapy (IMRT); Stereotactic Body Radiation Therapy (SBRT); Proton Therapy

3) By Surgery: Pleurectomy Or Decortication (P/D); Extrapleural Pneumonectomy (EPP); Cytoreductive Surgery; Palliative Surgery

4) By Immunotherapy: Immune Checkpoint Inhibitors; Monoclonal Antibodies; Tumor Vaccines; Adoptive Cell Therapy

5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Angiogenesis Inhibitors; Mesothelin-Targeted Agents; Gene Therapy-Based Approaches

What Are The Latest Industry Trends Transforming The Malignant Mesothelioma Market?

Leading companies active in the malignant mesothelioma market are concentrating on developing advanced therapeutic approaches, such as monoclonal antibody treatments, to suppress tumor growth and enhance treatment accuracy. Monoclonal antibodies are lab-created proteins designed to mimic the immune system’s capability to detect and target specific antigens, like those found on cancer cells. For example, in November 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, obtained supplemental approval in Japan for the expanded application of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody for treating malignant mesothelioma (excluding malignant pleural mesothelioma). This approval establishes Opdivo as a new treatment option for this condition, where standard treatments had not been previously defined. Opdivo was also given orphan drug status for this indication, emphasizing its potential to address a significant medical necessity.

Which Leading Players Are Enhancing Their Malignant Mesothelioma Market Presence Worldwide?

Major companies operating in the malignant mesothelioma market are AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-report

Which Region Currently Holds The Largest Share Of The Malignant Mesothelioma Market?

North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Malignant Mesothelioma Market Report:

https://www.thebusinessresearchcompany.com/customise?id=22046&type=smp

Browse Through More Reports Similar to the Global Malignant Mesothelioma Market 2025, By The Business Research Company

Lung Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Lung Cancer Diagnostic And Screening Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Small Cell Lung Cancer Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795